Adimab

Not all antibody heterodimerization approaches are equal. While traditional knob-into-hole methods often yield just 52% purity, Adimab’s Chain Exchange (ChEx) technology achieves 97% purity. Our white paper benchmarks ChEx data against current standards, demonstrating: 📈 97% purity (via SEC/iEX data) with minimal purification complexity 🛡️ Thermal stability comparable to wild-type IgG 🎯 Confirmed, robust dual-target binding Download the white paper to see the benchmarking data for yourself.

Traditional antibody heterodimerization forces an impossible choice: accept extensive purification to remove mispaired species, or use mutations that compromise Fc stability. You shouldn't have to compromise quality for manufacturability. In our white paper, we describe how Chain Exchange technology solves this structural dilemma, delivering high-purity multispecifics while preserving critical Fc characteristics.

Exploring a 12×12 mutlispecific antibody matrix shouldn't require 144 individual transfections. When every antibody pairing requires custom optimization, scaling your format exploration becomes operationally impractical. Our white paper demonstrates how Adimab’s Chain Exchange technology bypasses this bottleneck, allowing your team to systematically evaluate vast matrix combinations without overloading your lab's capacity.

See how our integrated yeast presentation and engineering platform accelerates your antibody discovery programs. Traditional discovery means cycling between formats and optimizing leads one at a time. Our yeast-based platform generates fully human antibodies directly in native formats, progressing multiple lineages forward together to eliminate bottlenecks and compress timelines. The result is antibodies ready for therapeutic development, without the wait.

Discover how yeast-based selections generate fully human antibodies more easily. Traditional antibody discovery: isolate → reformat → characterize → optimize → validate. What if you could skip the reformatting step? Our yeast-based platform generates fully human antibodies directly in native formats. No reformatting, no humanization delays. Learn how 675+ discovery programs have been accelerated with our approach.

Most teams can engineer a bispecific antibody, but determining the right architecture costs months in development time. The same binders in different formats can show significant differences in target cell binding and functional activity. Traditional assembly forces you to guess which geometry will work. With the Adimab platform, you can seamlessly explore multiple formats while avoiding: 🔬 Mispairing and homodimer contamination ⏳ Months of trial-and-error iteration 📉 Unnecessary development risk Download our white paper to learn how we optimize your therapeutic format efficiently.